SYF6dd36d0c1928413180aeed4ccd6fef59Registry ID: 2023-503700-81-00|RecruitingPhase 4
Palliation of Dyspnea and Cough using Morphine in patients with Fibrotic Interstitial Lung Disease
Aarhus University Hospital
Loading search results
interventional
N/A
1 country
3
The main object of the study is to examine the effect of 4 weeks treatment with slow-release morphine compared to placebo on the perception of breathlessness in patients with fibrotic interstitial lung diseases.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 22, 2023
Actual (reported)The change in average VAS score for dyspnea the last 24-hours (baseline) measured over a week and after 4 weeks treatment with morphine.
Change in walking distance during 6-minute walk test from baseline to follow-up after 4 weeks of treatment
Change in level of desaturation at 6-minute walk test from baseline to follow-up after 4 weeks of treatment
Change in BORG dyspnea scale at 6-minute walk test from baseline to follow-up after 4 weeks of treatment
Change in questionnaire (VAS for tough, Leicester Cough Questionnaire, King's Brief Lung Disease Questionnaire, COPD assessment Score) from baseline to follow-up after 4 weeks of treatment
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
Malfin, depottabletter
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
PROLONGED-RELEASE TABLET
View registry recordFormulated product
Contalgin, depottabletter
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
PROLONGED-RELEASE TABLET
View registry recordFormulated product
Contalgin, depottabletter
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
PROLONGED-RELEASE TABLET
View registry recordFormulated product
MST CONTINUS 5 mg prolonged-release tablets
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
PROLONGED-RELEASE TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
Malfin, depottabletter
Named ingredient: Morphine sulfate
View registry recordContalgin, depottabletter
Named ingredient: Morphine sulfate
View registry recordContalgin, depottabletter
Named ingredient: Morphine sulfate
View registry recordMST CONTINUS 5 mg prolonged-release tablets
Named ingredient: Morphine sulfate
View registry recordRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Aarhus University Hospital
Aarhus N, 8200, Denmark
Odense University Hospital
Odense C, 5000, Denmark
Gentofte Hospital
Hellerup, 2900, Denmark
Sissel Kronborg-White
First Submitted
November 22, 2023
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.